Xspray Pharma: Raising SEK83m - Redeye

Yesterday's rights issue announcement aligned closely to the scenario we discussed in our previous research update. The dilution is relatively limited at 9-11%, compared to our estimate of 10%. With the cash raise out of the way, the two upcoming PDUFA dates is likely to start monopolizing the markets attention.

Länk till analysen i sin helhet: https://www.redeye.se/research/1158206/xspray-pharma-raising-sek83m?utm_source=finwire&utm_medium=RSS